8-K: Celularity Inc. Private Placement Agreement Expires Due to Non-Receipt of Funds

Celularity Inc.'s private placement agreement with an institutional investor has expired due to the non-receipt of the subscription amount, resulting in the cancellation of the planned sale of shares and warrants.

Summary

• Celularity Inc. had previously announced a private placement agreement on January 3, 2025, with an institutional investor.
• The agreement involved the sale of 1,263,157 shares of Class A common stock and warrants to purchase an additional 1,263,157 shares.
• The purchase price was set at $2.375 per share and accompanying warrants.
• On January 23, 2025, Celularity notified the investor that the agreement had expired.
• The expiration was due to the company not receiving the subscription amount from the investor.
• As a result, the private placement will not be completed.

Sentiment

Score: 3

Explanation: The failure of a private placement is a negative event, indicating potential financial challenges for the company. The sentiment is therefore negative.

Negatives

• The private placement of 1,263,157 shares and warrants has been cancelled.
• The company did not receive the expected funds from the institutional investor.

Risks

• The failure to complete the private placement may impact Celularity's funding and growth plans.
• The company may need to seek alternative financing options.

Future Outlook

The company will likely need to explore alternative financing options given the termination of the private placement.

Management Comments

• Robert J. Hariri, M.D., Ph.D., Chairman and CEO, signed the report on behalf of Celularity Inc.

Industry Context

The failure of a private placement can be a setback for a company, especially in the biotech sector where funding is crucial for research and development. This may lead to increased scrutiny from investors.

Comparison to Industry Standards

• Private placements are a common method for biotech companies to raise capital, but they are not guaranteed to close.
• The failure of a private placement is not uncommon, but it can negatively impact investor confidence.
• Other biotech companies such as Xometry and Ginkgo Bioworks have successfully completed private placements, highlighting the importance of investor commitment.

Stakeholder Impact

• Shareholders may be concerned about the company's ability to secure funding.
• Employees may be impacted by potential changes in the company's financial situation.
• Creditors may reassess their risk exposure to the company.

Next Steps

• Celularity Inc. will likely need to seek alternative financing options.
• The company may need to reassess its financial strategy.

Key Dates

Keywords

private placement, securities purchase agreement, common stock, warrants, institutional investor, financing, Celularity Inc.